Strides Arcolab has received approval from the United States Food & Drug Administration (US FDA) for Buspirone hydrochloride tablets USP, 5 mg, 10 mg, 15 mg and 30 mg. According to IMS data as on September 2013, the US market for generic Buspirone tablets is approximately $65 million.
The product will be manufactured at the company’s oral dosage facility at Bangalore and marketed directly by Strides in the US Market.
EP News Bureau– Mumbai